Quantcast

Latest Etanercept Stories

2014-08-21 08:28:17

INDIANAPOLIS, Aug. 21, 2014 /PRNewswire/ -- -- Ixekizumab met all primary and key secondary objectives across three pivotal studies of 3,866 patients, the largest Phase 3 moderate-to-severe plaque psoriasis program to date -- Ixekizumab was superior to etanercept on all measures of skin clearance in both active comparator studies -- Lilly plans regulatory submissions for ixekizumab in 1(st) half of 2015 Eli Lilly and Company's (NYSE: LLY)...

2014-08-12 16:27:31

DUBLIN, Aug. 12, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Biological Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 Biological drugs are typically derived from living cells and are used in the treatment and prevention of various diseases such as cancer, blood-related diseases, auto-immune diseases and other medical disorders....

2014-08-05 08:35:59

LONDON, Aug. 5, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growthhttp://www.reportbuyer.com/pharma_healthcare/treatments/systemic_psoriasis_therapeutics_major_developed_markets_2020_continued_uptake_biologics_novel_pipeline_drugs_drive_growth.htmlSystemic Psoriasis Therapeutics in Major Developed Markets to 2020 -...

2014-07-16 08:28:14

Company Advances Development as Part of Collaboration with Baxter International's Biopharmaceutical Business REDWOOD CITY, Calif., July 16, 2014 /PRNewswire/ -- Coherus BioSciences, Inc. announced the start of its Phase 3 trial of CHS-0214, a proposed biosimilar of etanercept (Enbrel®), in chronic plaque psoriasis (the RaPsOdy trial). This announcement follows the recent initiation of a Phase 3 trial of CHS-0214 in rheumatoid arthritis. The Phase 3 psoriasis trial is a 48-week,...

2014-07-09 16:28:56

- Results of two Phase III psoriasis studies show secukinumab, the first psoriasis IL-17A inhibitor filed with regulatory bodies, met all co-primary and key secondary endpoints[1] EAST HANOVER, N.J., July 9, 2014 /PRNewswire/ -- Novartis today announced that The New England Journal of Medicine (NEJM) published the results from two pivotal Phase III studies evaluating the interleukin-17A (IL-17A) inhibitor secukinumab (AIN457). Secukinumab met all primary and key secondary...

2014-06-23 12:29:24

Coherus Advances Development as Part of Collaboration with Daiichi Sankyo and Baxter REDWOOD CITY, Calif., June 23, 2014 /PRNewswire/ -- Coherus BioSciences, Inc. announced the start of its Phase 3 trial of CHS-0214, an investigational etanercept biosimilar, in rheumatoid arthritis (RA). The Phase 3 trial is a randomized, double-blind, active-control, parallel-group, multicenter, global study in subjects with active RA who have demonstrated an inadequate response to methotrexate....

2014-06-01 23:01:09

LifeScienceIndustryResearch.com adds Latest Report on “Frontier Pharma: Psoriasis – Identifying and Commercializing First-in-Class Innovation” to its store. Dallas, TX (PRWEB) June 01, 2014 Psoriasis is a chronic, inflammatory disease triggered by deregulated Thymus-derived (T) cells, resulting inflammation and benign hyperplasia of keratinocytes within the skin. Manifestations of affected skin are red, thickened plaques with an overlying silver-white scale, which significantly...

2014-05-21 23:03:36

New research report “The Future of Biosimilars: mapping critical uncertainties and the impact of future events” by FirstWord is now available at MarketPublishers.com. London, UK (PRWEB) May 21, 2014 At present, the world biosimilars industry is on the verge of considerable progress and is deemed to have lucrative growth prospects. Certain policy changes are predicted to play an essential part in the development of the world biosimilars industry moving forward. A number of changes are...

2014-05-05 12:28:40

European Dermatologists Indicate that Fewer than Half of Their Severe Patients are being Treated with a Biologic, According to Findings from Decision Resources Group BURLINGTON, Mass., May 5, 2014 /PRNewswire/ -- Decision Resources Group finds that the use of biologics for the treatment of psoriasis among dermatologists has remained relatively flat since 2011 in the major European markets (France, Germany, Italy, Spain and the United Kingdom), with less than half of severe patients being...

2014-04-30 12:30:11

Expert Opinion Indicates That Humira and Cimzia Have the Best Clinical Profiles of Key Marketed Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., April 30, 2014 /PRNewswire/ --Decision Resources Group finds that, when asked to select the top three most persuasive end points when prescribing a new drug for psoriatic arthritis (PsA), the highest percentages of surveyed United States and European rheumatologists selected the American College of Rheumatology (ACR)...


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related